These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. A case of aripiprazole and tardive dyskinesia. Abbasian C, Power P. J Psychopharmacol; 2009 Mar; 23(2):214-5. PubMed ID: 18515468 [Abstract] [Full Text] [Related]
25. Aripiprazole augmentation in the management of residual symptoms in clozapine-treated outpatients with chronic schizophrenia: An open-label pilot study. Mitsonis CI, Dimopoulos NP, Mitropoulos PA, Kararizou EG, Katsa AN, Tsakiris FE, Katsanou MN. Prog Neuropsychopharmacol Biol Psychiatry; 2007 Mar 30; 31(2):373-7. PubMed ID: 17092620 [Abstract] [Full Text] [Related]
26. Safety and tolerability of once monthly aripiprazole treatment initiation in adults with schizophrenia stabilized on selected atypical oral antipsychotics other than aripiprazole. Potkin SG, Raoufinia A, Mallikaarjun S, Bricmont P, Peters-Strickland T, Kasper W, Baker RA, Eramo A, Sanchez R, McQuade R. Curr Med Res Opin; 2013 Oct 30; 29(10):1241-51. PubMed ID: 23822566 [Abstract] [Full Text] [Related]
27. A randomized, double-blind, placebo-controlled study of aripiprazole for the treatment of psychosis in nursing home patients with Alzheimer disease. Streim JE, Porsteinsson AP, Breder CD, Swanink R, Marcus R, McQuade R, Carson WH. Am J Geriatr Psychiatry; 2008 Jul 30; 16(7):537-50. PubMed ID: 18591574 [Abstract] [Full Text] [Related]
28. Use of aripiprazole in tardive dyskinesia: an open label study of six cases. Rajarethinam R, Dziuba J, Manji S, Pizzuti A, Lachover L, Keshavan M. World J Biol Psychiatry; 2009 Jul 30; 10(4 Pt 2):416-9. PubMed ID: 19492247 [Abstract] [Full Text] [Related]
30. The efficacy, safety, and tolerability of aripiprazole for the treatment of schizoaffective disorder: results from a pooled analysis of a sub-population of subjects from two randomized, double-blind, placebo-controlled, pivotal trials. Glick ID, Mankoski R, Eudicone JM, Marcus RN, Tran QV, Assunção-Talbott S. J Affect Disord; 2009 May 30; 115(1-2):18-26. PubMed ID: 19230981 [Abstract] [Full Text] [Related]
31. Open-label aripiprazole in the treatment of acute bipolar depression: a prospective pilot trial. McElroy SL, Suppes T, Frye MA, Altshuler LL, Stanford K, Martens B, Leverich GS, Post RM, Keck PE. J Affect Disord; 2007 Aug 30; 101(1-3):275-81. PubMed ID: 17229469 [Abstract] [Full Text] [Related]
32. Psychosocial functioning in patients with schizophrenia treated with aripiprazole - an office-based real-world setting. Results from the German post-marketing surveillance study. Bergmann F, Zacher A, Nass A, Urban R, Werner C, Spevakné-Göröcs T, Kungel M, Ebrecht M, Modell S. Pharmacopsychiatry; 2009 May 30; 42(3):101-8. PubMed ID: 19452378 [Abstract] [Full Text] [Related]
33. Aripiprazole in schizophrenia and schizoaffective disorder: A review. Stip E, Tourjman V. Clin Ther; 2010 May 30; 32 Suppl 1():S3-20. PubMed ID: 20152550 [Abstract] [Full Text] [Related]
39. An open-label assessment of aripiprazole in the treatment of PTSD. Robert S, Hamner MB, Durkalski VL, Brown MW, Ulmer HG. Psychopharmacol Bull; 2009 May 30; 42(1):69-80. PubMed ID: 19204652 [Abstract] [Full Text] [Related]